Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 20 September 2022, 23:50 HKT/SGT
Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference

Gaithersburg, MD, USA and Suzhou BioBay, China, Sept 20, 2022 - (ACN Newswire) - Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on delivery of novel RNAi therapies for cancer, and its GalAhead(TM) platform and programs, at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference. The conference will take place on September 21 and 22, 2022 with workshops on September 20, 2022 at Copthorne Tara Hotel, London, UK.

Presentation Details

Presentation Title: Delivery of Novel siRNA Constructs for Treating Cancer
Presenter: Dr. David Evans, Chief Scientific Officer, Sirnaomics
Time/Date: 15:20 GMT on Wednesday, September 21, 2022
Presentation Topics:
-- Creating novel siRNA constructs for cancer treatment
-- Introduction to Sirnaomics' polypeptide nanoparticle delivery system (PNP-IT)
-- Introduction to STP705, Sirnaomics' lead oncology siRNA therapeutic targeting TGF-beta1/COX-2
-- Discussion of novel siRNA therapeutics targeting other oncology indications

Presentation Title: GalAhead(TM) Therapeutic Platform and Programs
Presenter: Dr. Jack Wei, Senior Director, Sirnaomics
Time/Date: 16:30 GMT on Thursday, September 22, 2022
Presentation Topics:
-- Introduction to GalAhead(TM), Sirnaomics' GalNAc-RNAi therapeutic platform
-- Miniaturized RNAi (mxRNA) as a key technological component of the platform
-- Validation of technology in vivo and in vitro
-- Progress report on GalAhead(TM)-based programs

For more information about Sirnaomics' presentation, please visit the event website at

About Sirnaomics

Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic for its core product, STP705. Learn more at

Investor Relations:
Nigel Yip, MBA
Chief Financial Officer, China, Sirnaomics

US Media Contact:
Alexis Feinberg
Tel: +1 203 939 2225

Asia Media Contact:
Bunny Lee
Tel: +852 3150 6707

Topic: Press release summary Sectors: BioTech, Healthcare & Pharm
From the Asia Corporate News Network

Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Latest Press Releases
MHI Group Delivers Two Large-Capacity Centrifugal Chillers for Singapore's Marina Bay District Cooling System  
Tuesday, October 4, 2022 10:58:00 AM
Rinnai and Toyota Start Exploring Hydrogen-Powered Cooking Methods  
Tuesday, October 4, 2022 10:02:00 AM
Bio Farma secures Multi-year Purchase Contract from UNICEF for its novel Oral Polio Vaccine type 2 (nOPV2)  
Oct 4, 2022 07:00 HKT/SGT
Gradiant, Global Water Solutions Provider, Expands Australia Presence and Capabilities  
Oct 4, 2022 06:55 HKT/SGT
Neste, Idemitsu Kosan, CHIMEI and Mitsubishi Corporation join forces to create a renewable plastics supply chain  
Monday, October 3, 2022 4:11:00 PM
Global Web 3.0 Gaming Platform ITSBLOC's $ITSB to Be Listed on MEXC  
Oct 3, 2022 15:00 HKT/SGT
Korindo in its Transition to an Eco-Friendly Company  
Oct 3, 2022 13:00 HKT/SGT
JCB Launches Kiwami Experience Exclusive Program  
Oct 3, 2022 11:00 HKT/SGT
Rovanpera crowned youngest ever champion with TOYOTA GAZOO Racing  
Monday, October 3, 2022 10:15:00 AM
EC Healthcare Acquires Multi-Disciplinary Healthcare Services Chain in Hong Kong  
Oct 3, 2022 10:08 HKT/SGT
More Press release >>
More >>
 News Alerts
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: